Petr Ho has over 20 years of senior business development management experience in biopharmaceutical industry, leading identification, evaluation, negotiation, and execution of collaborations, licenses, and acquisitions. His previous professional experiences include Chief Business Officer at Engine Biosciences; VP BD at Nektar Therapeutics; Senior Director BD at BeiGene; Director BD at Iovance Biotherapeutics, and IImmunoCellular Therapeutics, and associate/analyst positions with D.E. Shaw, Allergan, and Prudential Equity Group.

Peter holds a Ph.D. in Biology from University of California, San Diego, an MBA from UCLA Anderson School of Management, and a BS in Chemistry and Biology from University of California, Irvine.